Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 5Terminated 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Breast 1

Conditions

Breast Neoplasms 34Neoplasm Metastasis 7Neoplasms 4Urinary Bladder Neoplasms 3Stomach Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Esophageal Neoplasms 2Carcinoma, Squamous Cell 2Breast Neoplasms, Male 2Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Skin Neoplasms 1Recurrence 1Prostatic Neoplasms 1Metastatic Breast Cancer With Intracranial Metastases 1Melanoma 1Inflammatory Breast Neoplasms 1Her2 Positive Metastatic Breast Cancer 1Head and Neck Neoplasms 1HER2 Positive Esophagogastric Cancer 1GastroEsophageal Cancer 1Esophageal Squamous Cell Carcinoma 1Diarrhea 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal, Breast 1Carcinoma 1Breast Diseases 1Brain Neoplasms 1

Interventions

Capecitabine 27pembrolizumab 19Oxaliplatin 19Fluorouracil 17Cisplatin 17Trastuzumab 14Docetaxel 14Leucovorin 11Paclitaxel 8Irinotecan 8S 1 (combination) 7Epirubicin 6Cyclophosphamide 5tegafur-gimeracil-oteracil 4aldesleukin 4Hyperthermic Intraperitoneal Chemotherapy 4titanium silicide 3spartalizumab 3fludarabine phosphate 3fludarabine 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Ramucirumab 3Nivolumab 3Indocyanine Green 3Gemcitabine 3Carboplatin 3Albumin-Bound Paclitaxel 3Ado-Trastuzumab Emtansine 3vistusertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Stomach Neoplasms × Lapatinib × Clear all
NCT01123473 2016-10-12

Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Terminated
29 enrolled
Gastrointestinal

Stomach Neoplasms

NCT01705340 2013-09-30

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Terminated
60 enrolled
BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡